Cargando…
Targeting activated protein C to treat hemophilia
Hemophilia is a debilitating disease, marked by frequent, painful bleeding events, joint deterioration and early death. All current treatments consist of i.v. infusions of replacement factor or other procoagulant factors, and are incompletely effective, due in part to the short half-lives of the pro...
Autores principales: | Polderdijk, Stéphanie G.I., Baglin, Trevor P., Huntington, James A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams And Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548501/ https://www.ncbi.nlm.nih.gov/pubmed/28632502 http://dx.doi.org/10.1097/MOH.0000000000000364 |
Ejemplares similares
-
Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C
por: Jiang, Miao, et al.
Publicado: (2022) -
The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022) -
Mapping the prothrombin-binding site of pseutarin C by site-directed PEGylation
por: Üstok, Fatma Işık, et al.
Publicado: (2022) -
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022) -
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)